Publications

Search our bibliography using the filters on the right-hand side.

Displaying 201 through 250 of 436 publications.

Rausch DA, Levin M, Meyers J, Candrilli S, Yan S, Krishnarajah G, Patterson B. Cost of diagnosed herpes zoster complications in patients age ≥50 years: a US claims data analysis. Poster presented at the IAGG 2017 World Congress; July 23, 2017. San Francisco, CA. [abstract] Innov Aging. 2017 Jul; 1(Suppl 1):902. doi: 10.1093/geroni/igx004.3234

Buck PO, Meyers JL, Gordon LD, Parikh R, Kurosky SK, Davis KL. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect. 2017 Jul;145(10):2109-21. doi: 10.1017/S0950268817000887.

Talbird SE, La EM, Mauskopf J, Krueger WS, Altland A, Daniels VJ, Pillsbury M, Wolfson LJ. Modeling the impact of exogenous boosting on herpes zoster: an updated methodological review of the varicella zoster virus literature. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A325.

Talbird SE, La EM, Poston SA, Hogea CS. A budget-impact analysis of quadrivalent influenza vaccine use in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A73.

Curran D, Van Oorschot D, Buck PO, Patterson BJ, Lee BY, Yawn BP, Hicks KA, Carrico J. Cost-effectiveness analysis of Shingrix for vaccinating US adults against herpes zoster. Presented at the ACIP Herpes Zoster Working Group; May 2017. Atlanta, GA.

Johnson KD, Jiang Y, Weiss T, Graham J. Herpes zoster vaccine effectiveness and waning of effectiveness. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A326.

Brogan AJ, Talbird SE, Davis AE, Thommes EW, Meier G. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: a dynamic transmission modeling approach. Hum Vaccin Immunother. 2017 Mar 4;13(3):533-42. doi: 10.1080/21645515.2016.1242541

Graham J, Johnson K, Jiang Y, Weiss T. Comparing the estimated potential health impact of 2 herpes zoster vaccines in the United States. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 27, 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3a):S3.

Hutchinson AB, Hicks KA, Yaylali E, Tucker E, Jacobson E, Sansom SL. Cost-effectiveness of HIV screening of heterosexuals in the United States. Poster presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI); February 14, 2017. Seattle, WA.

van der Straten A, Cheng H, Agot K, Ahmed K, Weinrib R, Manenzhe K, Owino F, Minnis A. Preference and choice of multipurpose prevention technologies in young African women. Poster presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI); February 13, 2017. Seattle, WA.

O'Leary A, DiNenno E, Honeycutt A, Allaire B, Neuwahl S, Hicks K, Sansom S. Contribution of anal sex to HIV prevalence among heterosexuals: a modeling analysis. AIDS Behav. 2017 Jan 5. doi: 10.1007/s10461-016-1635-z

Korsnes JS, Goodwin BB, Murray M, Candrilli SD. Antiretroviral treatment switching and its association with economic outcomes and adverse treatment effects among commercially insured and Medicaid-enrolled patients with HIV in the United States. Ann Pharmacother. 2016 Dec;50(12):989-1000.

Yaylali E, Farnham P, Sansom S, Hicks KA, Honeycutt A, Tucker E. Using the HOPE model for evaluating HIV interventions in the US. Presented at the 2016 INFORMS Annual Meeting; November 13, 2016. Nashville, TN.

Willame C, Rosillon D, Zima J, Angelo MG, Stuurman AL, Vroling H, Boggon R, Bunge EM, Pladevall-Vila M, Baril L. Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Hum Vaccin Immunother. 2016 Nov;12(11):2862-71. doi: 10.1080/21645515.2016.1199308

Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Cost analysis of Raltegravir versus Atazanavir/r or Darunavir/r for treatment-naive adults with HIV-1 infection in Spain. Poster presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A410.

Jacobson E, Hicks KA, Yaylali E, Chen YH, Sansom S. Effects of reaching national HIV/AIDS strategy viral load suppression goal on HIV incidence, by race and ethnicity, in the United States. Presented at the 38th Annual North American Meeting of the Society for Medical Decision Making; October 24, 2016. Vancouver, Canada.

Wilkins E, Fisher M, Brogan AJ, Talbird SE, La EM. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. HIV Med. 2016 Aug;17(7):505-15. doi: 10.1111/hiv.12349

Mao N, Lesher B, Liu Q, Qin L, Chen Y, Gao X, Earnshaw SR, McDade CL, Claudie C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. Clinicoecon Outcomes Res. 2016 Jun;8:275-85.

Davis AE, Brogan AJ, Goodwin BB. Cost analysis of raltegravir versus atazanavir/r or darunavir/r for treatment-naive adults with HIV-1 infection in the United States. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A214-5.

Buck PO, Gordon LD, Meyers J, Parikh R, Kurosky S, Davis KL. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease: a US database study. Poster presented at the National Foundation for Infectious Diseases 19th Annual Conference on Vaccine Research; April 2016. Bethesda, MD.

Yaylali E, Farnham P, Jacobson E, Allaire BT, Wagner DL, Hicks KA, Honeycutt AA, Sansom SL. Impact of improving HIV care and treatment and initiating PrEP in the US, 2015-2020. Poster presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI); February 24, 2016. Boston, MA.

Yaylali E, Farnham PG, Hicks KA, Honeycutt A, Sansom SL, Tucker EL. Developing a dynamic compartmental model of HIV in the United States. Poster presented at the INFORMS Annual Meeting; November 3, 2015. Philadelphia, PA.

Auzinger G, Playford GE, Graham CN, Knox HN, Weinstein D, Kantecki M, Schlamm H, Charbonneau C. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis. BMC Infect Dis. 2015 Oct 26;15:463. doi: 10.1186/s12879-015-1143-1

Chen YH, Yaylali E, Hicks KA, Tucker EL, Farnham PG, Sansom SL. Calibrating dynamic compartmental models of human immunodeficiency virus in the United States. Poster presented at the Society for Medical Decision Making (SMDM) 37th Annual North American Meeting; October 18, 2015. St. Louis, MO.

Reniers G, Armbruster B, Lucas A. Sexual networks, partnership mixing, and the female-to-male ratio of HIV infections in generalized epidemics: an agent-based simulation study. Demogr Res. 2015 Sep;33(15):425-50. doi: 10.4054/DemRes.2015.33.15

Puig-Barbera J, Tormos A, Trushakova S, Sominina A, Pisareva M, Ciblak MA, Badur S, Yu H, Cowling BJ, Burtseva E, GIHSN Group. The Global Influenza Hospital Surveillance Network (GIHSN): a new platform to describe the epidemiology of severe influenza. Influenza Other Respi Viruses. 2015 Jul 21. doi: 10.1111/irv.12335

Talbird SE, Brogan AJ, La EH, Perard R. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in France and Spain. Poster presented at the Health Technology Assessment international; June 14, 2015. Oslo, Norway.

Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients. Clin Ther. 2015 Jun 1;37(6):1317-28. doi: 10.1016/j.clinthera.2015.03.021

Kurosky SK, Reese ES, Candrilli SD. Recent trends in bacterial infection-related hospitalizations in the United States. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A274.

Qin L, Chen Y, Lesher B, Qifa L, Charbonneau C, Earnshaw SR, McDade CL, Mao N, Gao X. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected aspergillus invasive fungal infections in China. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A237.

Talbird SE, Graham JB, Mauskopf JA, Masseria C, Krishnarajah G. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases. J Manag Care Pharm. 2015 Jan;21(1):88-99.

Lucas A, Schackman BR, Ross EL, Yazdanpanah Y, Paltiel AD. The cost-effectiveness of targeting HIV pre-exposure prophylaxis based on partner treatment status in men who have sex with men in the US. Poster presented at the 36th Annual North American Meeting of the Society for Medical Decision Making; October 22, 2014. Miami, FL.

Brogan AJ, Smets E, Mauskopf JA, Manuel SA, Adriaenssen I. Cost-effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada. Pharmacoeconomics. 2014 Sep;32(9):903-17.

Wilkins E, Fisher M, Brogan AJ, Talbird SE. An analysis of cost and health outcomes associated with tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the United Kingdom. Poster presented at the 20th International AIDS Conference; July 20, 2014.

Puig-Barbera J, Natividad-Sancho A, Launay O, Burtseva E, Ciblak MA, Tormos A, Buiques-Vila A, Martinez-Ubeda S, Sominina A, GIHSN Group. 2012-2013 Seasonal influenza vaccine effectiveness against influenza hospitalizations: results from the global influenza hospital surveillance network. PLoS One. 2014 Jun 19;9(6):e100497.

Puig-Barbera J, Tormos A, Sominina A, Burtseva E, Launay O, Ciblak MA, Navtividad-Sancho A, Buigues-Vila A, Martinez-Ubeda S, Mahe C, GIHSN Group. First-year results of the Global Influenza Hospital Surveillance Network: 2012-2013 Northern hemisphere influenza season. BMC Public Health. 2014 Jun 5;14:564. doi: 10.1186/1471-2458-14-564.

Davis KL, Kurosky SK. Recent trends in incidence of infant pertussis hospitalization in the United States. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.

Davis KL, Kurosky SK. Recent trends in costs, length of stay, and mortality associated with infant pertussis hospitalization in the United States. Presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.

Kurosky SK, Davis KL, Karve SJ. Tetanus toxoid, reduced diphtheria toxoid, and acellular puertussis (TDAP) vaccine compliance among adolescents in the United States, 2010-2012. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.

Wilkins E, Fisher M, Brogan AJ, Talbird SE. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the United Kingdom. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A276.

Karve SJ, Krishnarajah G, Korsnes JS, Cassidy A, Candrilli SD. Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population. Hum Vaccin Immunother. 2014 Apr;10:1544-66. doi: 10.4161/hv.28704

Fletcher FE, Vidrine DJ, Tami-Maury I, Danysh HE, King RM, Buchberg M, Arduino RC, Gritz ER. Cervical cancer screening adherence among HIV-positive female smokers from a comprehensive HIV clinic. AIDS Behav. 2014 Mar;18(3):544-54. doi: 10.1007/s10461-013-0480-6

Tami-Maury I, Vidrine DJ, Fletcher FE, Danysh H, Arduino R, Gritz ER. Poly-tobacco use among HIV-positive smokers: implications for smoking cessation efforts. Nicotine Tob Res. 2013 Dec;15(12):2100-6. doi: 10.1093/ntr/ntt107.

Davis KL, Candrilli S. Recent trends in hospital costs, length of stay, and mortality associated with pediatric meningococcal disease in the United States. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A349.

Davis KL, Candrilli S. Recent trends in incidence and demographics of pediatric meningococcal disease in the United States. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A342.

Korsnes JS, Goodwin BB, Candrilli SD. The association between adherence to antiretroviral therapy and economic outcomes among commercially insured and medicaid hiv patients in the United States. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A348-9.

Brennan VK, Talbird SE, Beard SM, Brogan AJ, Flanagan D, Delpech V, Bosanquet N, Fisher M. The public health and economic impact from earlier diagnosis and earlier antiretroviral treatment of HIV in the UK. Poster presented at the 14th European AIDS Conference/EACS; October 16, 2013.

Villa M, Black S, Groth N, Rothman KJ, Apolone G, Weiss NS, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Crucitti A, Della Cioppa G, Scarpini E, Mavilio D, Mannino S. Safety of mf59-adjuvanted influenza vaccination in the elderly: results of a comparative study of mf59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy. Am J Epidemiol. 2013 Oct;178(7):1139-45.

Korsnes JS, Goodwin BB, Candrilli SD. Adherence to antiretroviral therapy and the association with treatment experience among commercially insured and Medicaid HIV patients in the United States. Poster presented at the American College of Clinical Pharmacy Annual Meeting; October 2013.

Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolanos-Meade J, Brown JMY, Walsh TJ, Horowitz MH, Kurtzberg J, Marr KA, Wingard JR. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. Am J Health Syst Pharm. 2013 Sep;70(17):1518-27.